Zobrazeno 1 - 10
of 525
pro vyhledávání: ''
Autor:
Christophe Borg, Olivier Bouché, Antoine Adenis, Jaafar Bennouna, Yann Touchefeu, François Ghiringhelli, Aurélie Bertaut, Julie Blanc, Thierry Conroy, Eric Francois, Jessica Gobbo, Pascal Artru
Publikováno v:
Clinical Colorectal Cancer. 21:e49-e61
Background and objectives : We have previously showed that for patients with wild-type RAS metastatic colorectal cancer (mCRC) progressing after bevacizumab plus chemotherapy, bevacizumab continuation plus a switch of chemotherapy is the most appropr
The Role of Intestinal Microbiota in Metastatic Colorectal Cancer Patients Treated With Capecitabine
Autor:
Romy Aarnoutse, Arnold Baars, Geert-Jan Creemers, Marjolein L. Smidt, Sander S. Rensen, Liselot B.J. Valkenburg-van Iersel, David J.M. Barnett, Janine Ziemons, John Penders, Anne Vievermans, Judith de Vos-Geelen, Giang N. Le, Aurelia C.L. Wildeboer, Hanneke J. H. M. J. Vestjens
Publikováno v:
Clinical Colorectal Cancer, 21(2), E87-E97. CIG Media Group, L.P.
Background Intestinal microbiota might interact with capecitabine and vice versa. Patients and methods 33 mCRC patients collected faecal samples before, during, and after three cycles capecitabine. Results Intestinal microbiota were not affected by c
Autor:
Amaury Druet, Caroline Viala, Yann Touchefeu, Jean-François Mosnier, Tamara Matysiak-Budnik, Erwan Corbineau
Publikováno v:
Clinical Colorectal Cancer. 21:e98-e101
Clinical Practice Points • Sinusoidal obstruction syndrome (SOS) is a life-threatening complication of oxaliplatin-based chemotherapy. • Nodular regenerative hyperplasia can be associated at a late stage of SOS, and should be suspected in case of
Autor:
Ainsley Barry, Tina Mills-Baldock, Sam Khan, Timothy Iveson, Athanasios Pouptsis, Chloe Holden, Anne Thomas, Bryony Eccles, Liyana Satterthwaite, Vasileios Angelis, Christina Karampera, Paul Ross, Sherif Abdel-Raouf, Alicja Synowiec, Kai-Keen Shiu, Maria Martinou, M Hill, Meera Chauhan, Mark Baxter, Chara Stavraka, Janet Graham, Sally Young
Publikováno v:
Clinical Colorectal Cancer. 20:342-349
BACKGROUND The orally administered combination trifluridine/tipiracil has been approved as third line treatment in mCRC, demonstrating survival benefit and acceptable toxicity profile in the phase III RECOURSE study. PATIENT AND METHODS We performed
Autor:
Prabhjot S Mundi, Arsenije Kojadinovic
Publikováno v:
Clinical Colorectal Cancer. 20:e249-e252
Autor:
N. Zanaletti, Susana Roselló Keränen, Debora Ierinò, Riccardo Giampieri, Michele De Tursi, Fabio Gelsomino, Ingrid Garajová, Alessio Cortellini, P. Vitale, Pasquale Lombardi, Emanuela Dell'Aquila, Teresa Troiani, Silvana Leo, Andrea Spallanzani, Giampiero Porzio, Ilaria Depetris, Federica De Galitiis, Olga Venditti, Angelica Petrillo, Michela Roberto, Francesca Di Pietro, Corrado Ficorella, Olga Nigro, Michele Ghidini, Roberto Filippi, Giampaolo Tortora, Antonio Avallone, Katia Cannita, Nicola Tinari, Gian Paolo Spinelli, Cristina Morelli, Lisa Salvatore, Giacomo Aimar, Fulgenzi Claudia, Alessandro Parisi, M. Ribelli, Valeria Zurlo, Federica Zoratto, Carla D'Orazio
Publikováno v:
Clinical Colorectal Cancer
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
BACKGROUND: Doublets plus antiepidermal growth factor receptors monoclonal antibodies (EGFRi) are widely considered the preferable first-line regimen in patients with left-sided RAS/BRAF wild-type metastatic colorectal cancer (mCRC), resulting superi
Autor:
Huabin Hu, Weiwei Li, Xiaoyu Xie, Jianxia Li, Miaomiao Ding, Jianwei Zhang, Zehua Wu, Jiayu Ling, Yue Cai, Yanhong Deng
Publikováno v:
Clinical Colorectal Cancer. 20:e240-e248
To evaluate the predictive implications and prognosis of mucinous adenocarcinoma (MAC) in locally advanced rectal cancer (LARC) with intensified neoadjuvant treatment.Individual patient data of LARC patients from 3 prospective clinical trials was ana
Publikováno v:
Clinical Colorectal Cancer. 20:e215-e225
Background Suboptimal completion of chemotherapy, which may involve reduced patient adherence, remains a serious issue and leads to reduced treatment efficacy. This study assessed the completion rates, risk factors for noncompletion, and cost impact
Autor:
Chad G. Ball, Patricia A. Tang, Nicholas A. Bosma, Derek Tilley, Caroline Speers, Winson Y. Cheung, Elijah Dixon, Daniel J. Renouf, Maclean Thiessen, Richard M. Lee-Ying
Publikováno v:
Clinical Colorectal Cancer. 20:e201-e209
Introduction In resected colonic liver metastasis (CLM), randomized studies of oxaliplatin-based chemotherapy have demonstrated improvements in disease-free survival (DFS), but not overall survival (OS). Additionally, oxaliplatin regimens have not be
Publikováno v:
Clinical Colorectal Cancer. 20:265-272
Liver-limited metastatic colorectal cancer is a potentially curable disease. Pathologic response (pR) to preoperative chemotherapy (CT) for colorectal liver metastases (CLM) is a surrogate endpoint for overall survival (OS). We conducted the first me